Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DADA inhibits tumor growth by enhancing CD8+ T cell stemness

ABSTRACT: To elucidate the mechanism by which DADA enhances the CD8+ T cell anti-tumor immune responses, we performed signal-cell RNA-sequencing (scRNA-seq) on tumor-infiltrating CD45+ T cells isolated from ctrl- or DADA-treated MC38-bearing mice.In this study, we found that diisopropylamine dichloroacetate (DADA) enhances CD8⁺ T cell-mediated anti-tumor immunity and promotes the accumulation of Tpex cells in the tumor microenvironment. Mechanistically, DADA promotes the conversion of pyruvate to acetyl-CoA by inhibiting pyruvate dehydrogenase kinase, thereby increasing oxidative phosphorylation (OXPHOS) levels and mitochondrial fitness, and ultimately enhancing the stemness of CD8⁺ T cells. In mouse models, DADA treatment significantly improves the efficacy of PD-1 blockade. Furthermore, the addition of DADA to the in vitro expansion system of chimeric antigen receptor (CAR)-T cells confers stemness characteristics to the cells, thereby enhancing their anti-tumor efficacy.

ORGANISM(S): Mus musculus

PROVIDER: GSE317913 | GEO | 2026/05/20

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

CD8+ T cells treated with DADA (40 μM) or an equal volume of DMSO solvent were harvested on day 6 of culture and subjected to transcriptome profiling analysis.

Project description:This study aimed to characterize the transcriptomic changes in CD8⁺ T cells following DADA treatment. Starting from day 3 of culture, the cells were treated with DADA (40 μM) or an equal volume of DMSO solvent. On day 6 of culture, the cells were harvested, total RNA was extracted, and high-throughput RNA sequencing (RNA-seq) was subsequently performed.

2026-05-20 | GSE317958 | GEO

Effect of MINK1 deficiency on gene expression in CD8+ OT-I TILs

Project description:The accumulation of ROS in the tumor microenvironment is a major driving factor for immunosuppression. While its detrimental effects on T cell activation are recognized, the precise molecular mechanisms remain unclear. In this study, we identify MINK1 as a ROS-responsive kinase in regulating CD8+ T cell-mediated anti-tumor immunity. We found that MINK1 ablation enhances the effector function of intratumoral CD8⁺ T cells by facilitate CD8+ effector T-cell differentiation, thereby enabling sustained tumor control. Mechanistically, MINK1 interacts with LATS1 and activates the Hippo pathway, thereby suppressing cytotoxic gene expression and inhibiting CD8+ T cell differentiation into effector subtypes. Finally, we proved that targeting MINK1 in both CAR-T and TCR-T cells could improve anti-tumor CD8+ T cell response in solid tumor models. Pharmacological inhibition of MINK1 also enhances anti-tumor immune responses in mice. Thus, this work uncovered MINK1 as a pivotal driver for CD8+ T cell dysfunction in tumors and highlights its potential as a therapeutic target for enhancing cancer immunotherapy.

2026-05-14 | GSE319767 | GEO

Effect of PP2A deficiency on gene expression in CD8+ T cells activation

2026-05-14 | GSE319766 | GEO

Wild-type versus trf4, trf5, and trf4-DADA mutant cells

Project description:Measurement of the relative changes of gene expression of S. cerevisiae cells lacking either trf4 (trf4delta) or trf5 (trf5delta), and trf4delta/TRF4-DADA mutants compared to wild-type (WT) cells using yeast oligo microarrays that contain features representing all annotated yeast ORFs, ncRNAs, introns, rRNA precursors, as well as some intergenic regions (IGRs) and tiled regions downstream of a few genes. Total RNA was isolated by hot phenol extraction from exponentially growing cells, and reverse transcribed with a mixture of random nonamers and oligo(dT) primers in the presence of amino-allyl dUTP/dNTP mixture. Cy5 fluorescently labeled cDNAs derived from total RNA isolated from either the trf4delta or the trf5delta mutants, and the trf4delta/TRF4-DADA mutants were then competitively hybridized with Cy3 labeled cDNAs from WT cells. cDNAs were hybridized on yeast oligo microarrays over night at 42 degrees in formamide-based hybridization buffer. Set of arrays organized by shared biological context, such as organism, tumors types, processes, etc. mutated gene: paralogous non-canonical poly(A) polymerases Trf4p and Trf5p forming TRAMP4 and TRAMP5 complexes

2009-07-15 | GSE16103 | GEO

trf4, trf5, and trf4-DADA mutant cells gene expression; Trf4p X-RIP-Chip

Project description:This SuperSeries is composed of the following subset Series: GSE16103: Wild-type versus trf4, trf5, and trf4-DADA mutant cells GSE16105: Trf4p in vivo crosslinking and ribonucleoprotein-immunopurification-chip analysis (X-RIP-Chip) Refer to individual Series

2010-06-24 | E-GEOD-16107 | biostudies-arrayexpress

Wild-type versus trf4, trf5, and trf4-DADA mutant cells

2010-06-24 | E-GEOD-16103 | biostudies-arrayexpress

Dietary restriction promotes anti-tumor immunity via T cell mediated ketone body metabolism

Project description:Diet can shape immune function in vivo, but the molecular mechanism remains poorly defined. In this study, we investigated how a reduction in food intake (hereafter referred to as dietary restriction or DR) affects CD8+ T cell function in multiple models. We found that DR reduced tumor burden in mice in a CD8+ T cell-dependent manner, indicating that the anti-tumor effects of DR are mediated by the immune system. Consistent with this observation, DR increased CD8+ T cell effector function, including production of interferon-γ and granzyme B. Moreover, analysis of tumor infiltrating CD8+ T cells showed DR led to a decrease in markers of T cell exhaustion (PD1, TIM3, TOX) and an increase in markers of cell stemness (LY108, TCF1). In a model of Listeria infection, we further showed that DR enhances CD8+ T cell mitochondrial fitness and bioenergetic capacity, indicating that DR impacts both CD8+ T cell metabolism and effector function. Using stable isotope tracing, we identified that CD8+ T cells from mice on DR preferentially consumed the ketone body β-hydroxybutyrate (βOHB), which is elevated 3-fold in serum of in mice on DR relative to ad libitum-fed mice. Notably, the effects of DR on anti-tumor immunity were attenuated in conditional knockout mice in which T cells are unable to catabolize βOHB, supporting that DR enhances anti-tumor immunity, in part, through increasing βOHB availability and metabolism by T cells. Current and future studies are exploring the effects of DR on different immune cell populations within tumors to further delineate the mechanism(s) by which DR enhances the immune response in cancer.

2025-01-28 | GSE267070 | GEO

A microRNA-regulated transcriptional state defines intratumoral CD8+T cells that respond to immunotherapy

Project description:Rising rates of advanced-stage colorectal cancer (CRC) and poor survival rates necessitate effective therapeutic options. Immune checkpoint inhibition (ICI), specifically anti-PD-1 therapy, shows potential, but clinical determinants of a positive response are suboptimal. Here, we identify microRNA-155 (miR-155) as necessary for CD8 T cell infiltrated tumors through an unbiased in vivo Crispr-Cas9 screen of tumor-antigen-specific CD8 T cell-related miRNAs. MiR-155 was necessary for a vital CD8 T cell differentiation cascade by repressing Ship-1, thereby inhibiting stemness and Tcf-1 while enhancing effector function and Cxcr6 expression, an indispensable aspect of anti-tumor and -PD-1 responses. Through a miR-155-dependent CD8 T cell transcriptional profile, we identified a gene signature that predicts anti-PD-1 responses across ten cancers. Taken together, our findings support a model whereby miR-155 serves as a central axis for CD8 T cell-dependent immunity in CRC and anti-PD-1 responses against multiple cancers that may be leveraged therapeutically or as a biomarker.

2025-02-10 | GSE262873 | GEO

Mannose enhances anti-PD-1 therapy efficacy in ovarian cancer via modulating gut microbial metabolite [Peritoneum]

Project description:The gut microbiome plays a critical role in enhancing the effectiveness of immune checkpoint blockade (ICB) therapy. Here, we demonstrate that oral supplementation with the prebiotics mannose slows tumor growth in immunocompetent mice in a manner dependent on the gut microbiota. This effect is associated with an increase in the abundance of Faecalibaculum. Mannose generates an immune-stimulatory tumor microenvironment (TME), characterized by a higher percentage of effector and memory CD8+ T cells, along with a notable immunoreactive gene expression signature. Crucially, mannose modulates the stemness program of CD8+ T cells and promotes the generation of progenitor exhausted CD8+ T cells (Tpex). Mechanistically, mannose enhances the production of the short-chain fatty acids (SCFA) propionate and butyrate by the gut microbiota. Administration of propionate and butyrate suppresses tumor progression and stimulates the expansion and differentiation of Tpex both in vivo and in vitro. Furthermore, mannose works synergistically with PD-1 blockade, resulting in tumor regression and enhanced differentiation of intratumoral Tpex into intermediate exhausted CD8+ T cells (Tex-int) and terminally exhausted CD8+ T cells (Tex-term). We also identified a gene signature related to mannose therapy that correlates with favorable responses to ICB across various cancers. Overall, our findings support the combination of mannose dietary supplementation with anti-PD-1 immunotherapy in treating ovarian cancer and suggest its potential for clinical application.

2025-03-17 | GSE285965 | GEO

Mannose enhances anti-PD-1 therapy efficacy in ovarian cancer via modulating gut microbial metabolite [CD8]

2025-03-17 | GSE285964 | GEO